The IL-23 inhibitors guselkumab (GUS), tildrakizumab (TIL), and risankizumab (RIS) represent the latest class of biologics to be approved for the management of moderate-to-severe psoriasis [3]. This evidence concerns the gene IL37 and psoriasis.